Disease · MONDO_0016262
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Positive Programmed Death Ligand 1 (PD-L1) Expression in Baseline Tumor Tissue | 27 of 159 | 0 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): deaths from any cause | 15 of 159 | 3 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): serious adverse events | 50 of 159 | 7 of 41 | 200 | NCT03565991 | Trial comparisons |
| Arm I Gem+Doce+Placebo vs Arm II Gem+Doce+Bev: Frequency and Severity of Adverse Effects as Assessed by the CTCAE Version 4.0 | 36 of 54 | 46 of 53 | 107 | NCT01012297 | Trial comparisons |
| Arm I vs Arm II: serious adverse events | 17 of 54 | 21 of 53 | 107 | NCT01012297 | Trial comparisons |
| Regimen 1 vs Regimen II: Number of Participants Who Experienced Death | 5 of 20 | 1 of 18 | 38 | NCT01533207 | Trial comparisons |
| Regimen 1 vs Regimen II: Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | 10 of 20 | 1 of 18 | 38 | NCT01533207 | Trial comparisons |
| Regimen 1 vs Regimen II: deaths from any cause | 5 of 20 | 1 of 18 | 38 | NCT01533207 | Trial comparisons |
| Regimen 1 vs Regimen II: Number of Participants With Recurrence | 8 of 20 | 8 of 18 | 38 | NCT01533207 | Trial comparisons |
| Regimen 1 vs Regimen II: serious adverse events | 5 of 20 | 0 of 18 | 38 | NCT01533207 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Confirmed PSA Response | 17 of 26 | 2 of 5 | 31 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Cancer Antigen 125 (CA-125) Response | 9 of 26 | 0 of 3 | 29 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Circulating Tumor Cell (CTC) Count Conversion | 11 of 13 | 1 of 2 | 15 | NCT03565991 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016262/comparisons